UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                          ----------------------------


                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): August 3, 2006

                           Critical Therapeutics, Inc.
               (Exact Name of Registrant as Specified in Charter)


          Delaware                    000-50767             04-3523569
(State or Other Jurisdiction         (Commission           (IRS Employer
      of Incorporation)              File Number)        Identification No.)


60 Westview Street, Lexington, Massachusetts                   02421
  (Address of Principal Executive Offices)                  (Zip Code)

       Registrant's telephone number, including area code: (781) 402-5700

                                 Not applicable
          (Former Name or Former Address, if Changed Since Last Report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






Item 2.02.   Results of Operations and Financial Condition.

         On August 3, 2006, Critical Therapeutics, Inc. (the "Company")
announced its financial results for the quarter ended June 30, 2006. The Company
also provided guidance regarding net cash expenditures for the third quarter of
2006 and operating expenses and stock-based compensation expense for the second
half of 2006. The full text of the press release issued in connection with the
announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

         The information in this Form 8-K and the Exhibit attached hereto shall
be deemed incorporated by reference in any registration statement previously or
subsequently filed by the Company under the Securities Act of 1933, as amended,
except to the extent that such information is superseded by information as of a
subsequent date that is included or incorporated by reference into such
registration statement.

Item 9.01.   Financial Statements and Exhibits.

       (d)   Exhibits

             See Exhibit Index attached hereto.





                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



Date:  August 3, 2006                   CRITICAL THERAPEUTICS, INC.

                                        By: /s/ Frank E. Thomas
                                            ------------------------------------
                                            Frank E. Thomas
                                            President






                                  EXHIBIT INDEX


Exhibit No.                Description
-------------              -----------------------------------------------------

99.1                       Press release dated August 3, 2006.